193 related articles for article (PubMed ID: 33506327)
61. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
Kalikaki A; Koutsopoulos A; Trypaki M; Souglakos J; Stathopoulos E; Georgoulias V; Mavroudis D; Voutsina A
Br J Cancer; 2008 Sep; 99(6):923-9. PubMed ID: 19238633
[TBL] [Abstract][Full Text] [Related]
62. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
63. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
[TBL] [Abstract][Full Text] [Related]
64. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
[TBL] [Abstract][Full Text] [Related]
65. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
[TBL] [Abstract][Full Text] [Related]
66. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
67. Pulmonary large cell carcinoma with rhabdoid phenotype.
Hiroshima K; Shibuya K; Shimamura F; Toyozaki T; Haga Y; Ohwada H; Iyoda A; Sekine Y; Iizasa T; Fujisawa T
Ultrastruct Pathol; 2003; 27(1):55-9. PubMed ID: 12554537
[TBL] [Abstract][Full Text] [Related]
68. Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases.
Evans M; O'Sullivan B; Smith M; Hughes F; Mullis T; Trim N; Taniere P
Pathol Oncol Res; 2019 Oct; 25(4):1401-1409. PubMed ID: 30094734
[TBL] [Abstract][Full Text] [Related]
69. [Gastric SWI/SNF complex deletion-associated undifferentiated carcinoma with rhabdoid phenotype: a clinicopathological and molecular analysis].
Jin YP; Wang L; Wang Y; Wu DY; Zhang H; Xia QX
Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1229-1234. PubMed ID: 36480831
[No Abstract] [Full Text] [Related]
70. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.
Mizera-Nyczak E; Dyszkiewicz W; Heider KH; Zeromski J
Tumour Biol; 2001; 22(1):45-53. PubMed ID: 11054026
[TBL] [Abstract][Full Text] [Related]
71. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
72. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
73. Lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases.
Demleitner M; Erlenbach-Wünsch K; Coras R; Erber R; Polifka I; Eyüpoğlu I; Fuchs F; Hartmann A; Agaimy A
Ann Diagn Pathol; 2023 Apr; 63():152082. PubMed ID: 36634550
[TBL] [Abstract][Full Text] [Related]
74. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ
Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547
[TBL] [Abstract][Full Text] [Related]
75. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.
Anagnostou VK; Lowery FJ; Zolota V; Tzelepi V; Gopinath A; Liceaga C; Panagopoulos N; Frangia K; Tanoue L; Boffa D; Gettinger S; Detterbeck F; Homer RJ; Dougenis D; Rimm DL; Syrigos KN
BMC Cancer; 2010 May; 10():186. PubMed ID: 20459695
[TBL] [Abstract][Full Text] [Related]
76. The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.
Krawczyk P; Ramlau R; Chorostowska-Wynimko J; Powrózek T; Lewandowska MA; Limon J; Wasąg B; Pankowski J; Kozielski J; Kalinka-Warzocha E; Szczęsna A; Wojas-Krawczyk K; Skroński M; Dziadziuszko R; Jaguś P; Antoszewska E; Szumiło J; Jarosz B; Woźniak A; Jóźwicki W; Dyszkiewicz W; Pasieka-Lis M; Kowalski DM; Krzakowski M; Jassem J; Milanowski J
J Cancer Res Clin Oncol; 2015 Jan; 141(1):61-8. PubMed ID: 25086987
[TBL] [Abstract][Full Text] [Related]
77. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
78. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
Daniele L; Cassoni P; Bacillo E; Cappia S; Righi L; Volante M; Tondat F; Inghirami G; Sapino A; Scagliotti GV; Papotti M; Novello S
J Thorac Oncol; 2009 Jun; 4(6):684-8. PubMed ID: 19404216
[TBL] [Abstract][Full Text] [Related]
79. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
[TBL] [Abstract][Full Text] [Related]
80. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
